Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BLFS Biolife Solutions Inc
- Stocks
- Healthcare
- NASDAQ: BLFS
Price (delayed)
$21.99
Market cap
$1.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$1.01B
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage
Highlights
BLFS's quick ratio has soared by 114% year-on-year
BLFS's net income has surged by 84% year-on-year and by 48% since the previous quarter
The company's revenue rose by 22% YoY but it fell by 3.5% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.biolifesolutions.com
Key stats
What are the main financial stats of BLFS
Market
Valuations
Earnings
Shares outstanding
47.56M
Market cap
$1.05B
Enterprise value
$1.01B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.93
Price to sales (P/S)
13.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.67
Revenue
$79.42M
Gross profit
$55.25M
Operating income
-$4.19M
Net income
-$10.41M
EBIT
-$10.69M
EBITDA
-$2.5M
Free cash flow
$9.73M
Per share
Balance sheet
Liquidity
EPS
-$0.36
EPS diluted
-$0.36
Free cash flow per share
$0.21
Book value per share
$7.5
Revenue per share
$1.68
TBVPS
$3.69
Total assets
$395.14M
Total liabilities
$42.52M
Debt
$26.95M
Equity
$352.62M
Working capital
$103.41M
Debt to equity
0.08
Current ratio
4.73
Quick ratio
3.53
Net debt/EBITDA
16.03
Margins
Efficiency
Dividend
EBITDA margin
-3.1%
Gross margin
69.6%
Net margin
-13.1%
Operating margin
-5.3%
Return on assets
-2.7%
Return on equity
-3.1%
Return on invested capital
-10.1%
Return on capital employed
-2.9%
Return on sales
-13.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLFS stock price
How has the Biolife Solutions stock price performed over time
Intraday
-0.27%
1 week
-1.65%
1 month
-1.96%
1 year
-4.35%
YTD
-15.29%
QTD
-3.72%
Financial performance
How have Biolife Solutions's revenue and profit performed over time
Revenue
$79.42M
Gross profit
$55.25M
Operating income
-$4.19M
Net income
-$10.41M
Gross margin
69.6%
Net margin
-13.1%
The net margin has surged by 87% year-on-year and by 47% since the previous quarter
The operating margin has soared by 84% YoY and by 39% from the previous quarter
BLFS's net income has surged by 84% year-on-year and by 48% since the previous quarter
BLFS's operating income has soared by 80% YoY and by 41% QoQ
Price vs fundamentals
How does BLFS's price correlate with its fundamentals
Growth
What is Biolife Solutions's growth rate over time
Valuation
What is Biolife Solutions stock price valuation
P/E
N/A
P/B
2.93
P/S
13.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.67
The EPS has surged by 76% year-on-year and by 18% since the previous quarter
BLFS's price to book (P/B) is 11% lower than its last 4 quarters average of 3.3 and 8% lower than its 5-year quarterly average of 3.2
The equity has grown by 6% YoY
The company's revenue rose by 22% YoY but it fell by 3.5% QoQ
The P/S is 12% lower than the last 4 quarters average of 14.9 and 6% lower than the 5-year quarterly average of 13.9
Efficiency
How efficient is Biolife Solutions business performance
The return on sales has surged by 86% year-on-year and by 43% since the previous quarter
The ROE has soared by 84% YoY and by 49% from the previous quarter
Biolife Solutions's return on assets has surged by 83% YoY and by 48% QoQ
The ROIC has soared by 76% YoY and by 43% from the previous quarter
Dividends
What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLFS.
Financial health
How did Biolife Solutions financials performed over time
BLFS's quick ratio has soared by 114% year-on-year
BLFS's current ratio has surged by 64% year-on-year and by 4.2% since the previous quarter
The debt is 92% smaller than the equity
The debt has declined by 34% year-on-year and by 11% since the previous quarter
Biolife Solutions's debt to equity has decreased by 33% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.